Skip to main content
Erschienen in: International Journal of Clinical Oncology 2/2016

30.07.2015 | Original Article

Significance of preoperative butyrylcholinesterase as an independent predictor of biochemical recurrence-free survival in patients with prostate cancer treated with radical prostatectomy

verfasst von: Takuya Koie, Chikara Ohyama, Shingo Hatakeyama, Atsushi Imai, Takahiro Yoneyama, Yasuhiro Hashimoto, Tohru Yoneyama, Yuki Tobisawa, Shogo Hosogoe, Hayato Yamamoto, Masato Kitayama, Kazuyoshi Hirota

Erschienen in: International Journal of Clinical Oncology | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Butyrylcholinesterase (BChE) is an alpha-glycoprotein found in the nervous system and liver. Its serum level is reduced in many clinical conditions, such as liver damage, inflammation, injury, infection, malnutrition, and malignant disease. In this study, we analyzed the potential prognostic significance of preoperative BChE levels in patients with prostate cancer (PCa) undergoing radical prostatectomy (RP).

Methods

We retrospectively evaluated 535 patients with PCa who underwent RP from 1996−2014 at a single institution. Serum BChE was routinely measured in all patients before operation. Covariates included age, preoperative laboratory data [prostate-specific antigen (PSA), hemoglobin, total protein, albumin, BChE, lactate dehydrogenase, C-reactive protein], clinical T, biopsy Gleason score, D’Amico risk classification, and RP with/without neoadjuvant therapy. Univariate and multivariate analyses were performed to identify clinical factors associated with biochemical recurrence-free survival (BRFS). Univariate analyses were performed using the Kaplan–Meier and log-rank methods, and multivariate analysis was performed using a Cox proportional hazard model.

Results

The median BChE level was 255 U/L (normal range 168–470 U/L). The median age of the enrolled patients was 68 years, and the median PSA level at diagnosis of PCa was 8.39 ng/mL. The median follow-up period was 65 months. The 5-year BRFS rate was 72.9 %. The 5-year BRFS rates in the BChE ≥168 and ≤ 167 U/L groups were 77.7 and 55.0 %, respectively (P < 0.001). In univariate analysis, BChE, cT, biopsy Gleason score, and D’Amico risk classification were significantly associated with BRFS. Multivariate analysis revealed that BChE was significantly associated with BRFS.

Conclusions

This study validated preoperative serum BChE levels as an independent prognostic factor for PCa after RP.
Literatur
1.
Zurück zum Zitat Huang GJ, Stein JP (2007) Open radical cystectomy with lymphadenectomy remains the treatment of choice for invasive bladder cancer. Curr Opin Urol 17:369–375CrossRefPubMed Huang GJ, Stein JP (2007) Open radical cystectomy with lymphadenectomy remains the treatment of choice for invasive bladder cancer. Curr Opin Urol 17:369–375CrossRefPubMed
2.
Zurück zum Zitat Makarov DV, Trock BJ, Humphreys EB et al (2007) Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 69:1095–1101CrossRefPubMedPubMedCentral Makarov DV, Trock BJ, Humphreys EB et al (2007) Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 69:1095–1101CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Kattan MW, Vickers AJ, Yu C et al (2009) Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized prostate cancer. Cancer 115:1005–1010CrossRefPubMedPubMedCentral Kattan MW, Vickers AJ, Yu C et al (2009) Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized prostate cancer. Cancer 115:1005–1010CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Yoneyama T, Ohyama C, Hatakeyama S et al (2014) Measurement of aberrant glycosylation of prostate specific antigen can improve specificity in early detection of prostate cancer. Biochem Biophys Res Commun 1448:390–396CrossRef Yoneyama T, Ohyama C, Hatakeyama S et al (2014) Measurement of aberrant glycosylation of prostate specific antigen can improve specificity in early detection of prostate cancer. Biochem Biophys Res Commun 1448:390–396CrossRef
5.
Zurück zum Zitat Lazzeri M, Haese A, Abrate A et al (2013) Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project. BJU Int 112:313–321CrossRefPubMed Lazzeri M, Haese A, Abrate A et al (2013) Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project. BJU Int 112:313–321CrossRefPubMed
6.
Zurück zum Zitat Santarpia L, Alfonsi L, Pasanisi F et al (2006) Predictive factors of survival in patients with peritoneal carcinomatosis on home parenteral nutrition. Nutrition 22:355–360CrossRefPubMed Santarpia L, Alfonsi L, Pasanisi F et al (2006) Predictive factors of survival in patients with peritoneal carcinomatosis on home parenteral nutrition. Nutrition 22:355–360CrossRefPubMed
7.
Zurück zum Zitat Lampón N, Hermida-Cadahia EF, Riveiro A et al (2012) Association between butyrylcholinesterase activity and low-grade systemic inflammation. Ann Hepatol 11:356–363PubMed Lampón N, Hermida-Cadahia EF, Riveiro A et al (2012) Association between butyrylcholinesterase activity and low-grade systemic inflammation. Ann Hepatol 11:356–363PubMed
8.
Zurück zum Zitat Chougule A, Hussain S, Agarwal DP (2008) Prognostic and diagnostic value of serum pseudocholinesterase, serum aspartate transaminase and serum alanine transaminase in malignancies treated by radiotherapy. J Cancer Res Ther 4:21–25CrossRefPubMed Chougule A, Hussain S, Agarwal DP (2008) Prognostic and diagnostic value of serum pseudocholinesterase, serum aspartate transaminase and serum alanine transaminase in malignancies treated by radiotherapy. J Cancer Res Ther 4:21–25CrossRefPubMed
9.
Zurück zum Zitat Koie T, Ohyama C, Yamamoto H et al (2014) Significance of preoperative butyrylcholinesterase as an independent predictor of survival in patients with muscle-invasive bladder cancer treated with radical cystectomy. Urol Oncol 32:820–825CrossRefPubMed Koie T, Ohyama C, Yamamoto H et al (2014) Significance of preoperative butyrylcholinesterase as an independent predictor of survival in patients with muscle-invasive bladder cancer treated with radical cystectomy. Urol Oncol 32:820–825CrossRefPubMed
10.
Zurück zum Zitat Mitsunaga S, Kinoshita T, Hasebe T et al (2008) Low serum level of cholinesterase at recurrence of pancreatic cancer is a poor prognostic factor and relates to systemic disorder and nerve plexus invasion. Pancreas 36:241–248CrossRefPubMed Mitsunaga S, Kinoshita T, Hasebe T et al (2008) Low serum level of cholinesterase at recurrence of pancreatic cancer is a poor prognostic factor and relates to systemic disorder and nerve plexus invasion. Pancreas 36:241–248CrossRefPubMed
11.
Zurück zum Zitat D’Amico AV, Whittington R, Malkowicz SB et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969–974CrossRefPubMed D’Amico AV, Whittington R, Malkowicz SB et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969–974CrossRefPubMed
12.
Zurück zum Zitat Koie T, Yamamoto H, Hatakeyama S et al (2011) Minimum incision endoscopic radical prostatectomy: clinical and oncological outcomes at a single institute. Eur J Surg Oncol 37:805–810CrossRefPubMed Koie T, Yamamoto H, Hatakeyama S et al (2011) Minimum incision endoscopic radical prostatectomy: clinical and oncological outcomes at a single institute. Eur J Surg Oncol 37:805–810CrossRefPubMed
13.
Zurück zum Zitat Epstein JI, Allsbrook WC Jr, Amin MB et al (2005) The 2005 International society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 29:1228–1242CrossRefPubMed Epstein JI, Allsbrook WC Jr, Amin MB et al (2005) The 2005 International society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 29:1228–1242CrossRefPubMed
14.
Zurück zum Zitat Urinary Bladder (2010) In: Edge SB, Byrd DR, Compton CC, Frits AG, Greene FL, Trotti A (eds) AJCC cancer staging manual, 7th edn. Springer, New York, pp 497–505 Urinary Bladder (2010) In: Edge SB, Byrd DR, Compton CC, Frits AG, Greene FL, Trotti A (eds) AJCC cancer staging manual, 7th edn. Springer, New York, pp 497–505
15.
Zurück zum Zitat Kinoshita S, Toyofuku M, Iida H et al (2001) Standardization of laboratory data and establishment of reference intervals in the Fukuoka Prefecture: a Japanese perspective. Clin Chem Lab Med 39:256–262CrossRefPubMed Kinoshita S, Toyofuku M, Iida H et al (2001) Standardization of laboratory data and establishment of reference intervals in the Fukuoka Prefecture: a Japanese perspective. Clin Chem Lab Med 39:256–262CrossRefPubMed
16.
Zurück zum Zitat Santarpia L, Grandone I, Contaldo F et al (2013) Butyrylcholinesterase as a prognostic marker: a review of the literature. J Cachexia Sarcopenia Muscle 4:31–39CrossRefPubMedPubMedCentral Santarpia L, Grandone I, Contaldo F et al (2013) Butyrylcholinesterase as a prognostic marker: a review of the literature. J Cachexia Sarcopenia Muscle 4:31–39CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Mitrache C, Passwerg JR, Libura J et al (2001) Anemia: an indicator for malnutrition in the elderly. Ann Hematol 80:295–298CrossRefPubMed Mitrache C, Passwerg JR, Libura J et al (2001) Anemia: an indicator for malnutrition in the elderly. Ann Hematol 80:295–298CrossRefPubMed
18.
Zurück zum Zitat Eggers H, Seidel C, Schrader AJ et al (2013) Serum C-reactive protein: a prognostic factor in metastatic urothelial cancer of the bladder. Med Oncol 30:705–711CrossRefPubMed Eggers H, Seidel C, Schrader AJ et al (2013) Serum C-reactive protein: a prognostic factor in metastatic urothelial cancer of the bladder. Med Oncol 30:705–711CrossRefPubMed
19.
Zurück zum Zitat Ogunkeye OO, Roluga AI (2006) Serum cholinesterase activity helps to distinguish between liver disease and non liver disease aberration in liver function tests. Pathophysiology 13:91–93CrossRefPubMed Ogunkeye OO, Roluga AI (2006) Serum cholinesterase activity helps to distinguish between liver disease and non liver disease aberration in liver function tests. Pathophysiology 13:91–93CrossRefPubMed
20.
21.
Zurück zum Zitat Klok MD, Jakobsdottir S, Drent ML (2006) The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes Rev 8:21–34CrossRef Klok MD, Jakobsdottir S, Drent ML (2006) The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes Rev 8:21–34CrossRef
22.
Zurück zum Zitat Ishizaki F, Hoque MA, Nishiyama T et al (2011) External validation of the UCSF-CAPRA (University of Calfornia, San Francisco, cancer of the prostate risk assessment) in Japanese patients receiving radical prostatectomy. Jpn J Clin Oncol 41:1259–1264CrossRefPubMed Ishizaki F, Hoque MA, Nishiyama T et al (2011) External validation of the UCSF-CAPRA (University of Calfornia, San Francisco, cancer of the prostate risk assessment) in Japanese patients receiving radical prostatectomy. Jpn J Clin Oncol 41:1259–1264CrossRefPubMed
23.
Zurück zum Zitat Tanaka N, Fujimoto K, Hirayama A et al (2011) Risk-stratified survival rates and prediction of biochemical recurrence after radical prostatectomy in a Nara, Japan, cohort study. Int J Clin Oncol 16:553–559CrossRefPubMed Tanaka N, Fujimoto K, Hirayama A et al (2011) Risk-stratified survival rates and prediction of biochemical recurrence after radical prostatectomy in a Nara, Japan, cohort study. Int J Clin Oncol 16:553–559CrossRefPubMed
Metadaten
Titel
Significance of preoperative butyrylcholinesterase as an independent predictor of biochemical recurrence-free survival in patients with prostate cancer treated with radical prostatectomy
verfasst von
Takuya Koie
Chikara Ohyama
Shingo Hatakeyama
Atsushi Imai
Takahiro Yoneyama
Yasuhiro Hashimoto
Tohru Yoneyama
Yuki Tobisawa
Shogo Hosogoe
Hayato Yamamoto
Masato Kitayama
Kazuyoshi Hirota
Publikationsdatum
30.07.2015
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 2/2016
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-015-0880-x

Weitere Artikel der Ausgabe 2/2016

International Journal of Clinical Oncology 2/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.